# Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides

> **NCT01187446** · PHASE1,PHASE2 · TERMINATED · sponsor: **Stanford University** · enrollment: 28 (actual)

## Conditions studied

- Cutaneous Lymphoma
- Cutaneous T-cell Lymphoma

## Interventions

- **RADIATION:** Total skin electron beam therapy (TSEBT)
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT01187446
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2013-08
- **Final completion:** 2014-02
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Business decision by funding source
- **Last updated:** 2017-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01187446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01187446, "Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01187446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*